Cassava Sciences, Inc. (SAVA)

Market Cap	957.01M
Revenue (ttm)	n/a
Net Income (ttm)	-97.22M
Shares Out	43.23M
EPS (ttm)	-2.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	951,804
Open	22.11
Previous Close	22.15
Day's Range	21.91 - 22.26
52-Week Range	12.32 - 32.10
Beta	-0.40
Analysts	Strong Buy
Price Target	124.00 (+460.07%)
Earnings Date	May 14, 2024

About SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Te...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: SAVA

Analyst Forecast

According to one analyst, the rating for SAVA stock is "Strong Buy" and the 12-month stock price forecast is $124.0.

Price Target

$124.0

(460.07% upside)

Analyst Consensus: Strong Buy